Skip to content
Bomb Report – Lifestyle
Author:
Aligos Therapeutics
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
April 14, 2026
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
March 7, 2026
←
Previous Page
1
2